Repatha Cost in Virginia 2026: Prices, Insurance, Medicaid, and Compounded Alternatives

What Is the Actual Repatha Price in Virginia Right Now?

Repatha's wholesale acquisition cost sits at approximately $580 per month in 2026, a figure Amgen has held relatively stable after the 2018 price cut of about 60% from the original launch price. Virginia retail pharmacies generally reflect this WAC, meaning cash-pay patients without any discount program face that same monthly ceiling. The 140 mg/mL autoinjector (used at 140 mg every two weeks or two pens at once for the 420 mg monthly dose) and the SureClick prefilled syringe are priced identically at the counter [1].

Statin-maximized patients who still need additional LDL reduction represent the primary population for this drug. The FOURIER trial (N=27,564) showed evolocumab reduced LDL-C by a mean of 59% from baseline on top of statin therapy, and cut the composite major adverse cardiovascular event endpoint by 15% relative to placebo over a median of 2.2 years (P<0.001) [2]. Those are the numbers that justify the cost conversation in the first place.

Virginia does not cap PCSK9 inhibitor prices at the state level beyond Medicaid rate-setting rules. Patients relying on commercial insurance, Medicare Part D, or cash pay each face a meaningfully different net cost. The sections below break down every pathway [3].

How Virginia Medicaid Covers Evolocumab

Virginia Medicaid (administered through Medallion 4.0 managed care organizations and fee-for-service) covers Repatha, but only after a prior authorization (PA) is approved [4]. PA criteria in Virginia generally require:

1. A confirmed diagnosis of heterozygous familial hypercholesterolemia (HeFH), homozygous FH (HoFH), or established atherosclerotic cardiovascular disease (ASCVD).
2. Documentation that the patient is on maximally tolerated statin therapy (or a documented statin intolerance with a reason on file).
3. An LDL-C that remains above 70 mg/dL for ASCVD patients or above 100 mg/dL for FH patients despite optimized therapy.
4. A note that ezetimibe was trialed or is contraindicated.

The American College of Cardiology's 2022 expert consensus pathway specifies that PCSK9 inhibition is appropriate when LDL-C remains at or above 70 mg/dL in very-high-risk ASCVD patients after maximally tolerated statin plus ezetimibe [5]. Virginia Medicaid PA language tracks closely with that threshold language.

Approval periods are typically 12 months, after which a renewal PA is required [4]. Patients whose plans are managed by MCOs (Anthem HealthKeepers Plus, Aetna Better Health of Virginia, Molina Healthcare of Virginia, Optima Health Community Care, or United Healthcare Community Plan) may face slightly different internal PA templates, but the underlying clinical criteria are standardized by DMAS [6]. Approved patients pay no more than a small nominal copay under Medicaid.

Denials can be appealed. A physician letter citing the ACC/AHA 2018 Blood Cholesterol Guideline's Class I recommendation for PCSK9 inhibition in very-high-risk ASCVD patients with LDL-C at or above 70 mg/dL often strengthens an appeal [7].

Commercial Insurance and Repatha in Virginia

Most commercial plans sold in Virginia place Repatha on a specialty or non-preferred specialty tier, which typically means the highest cost-sharing tier before prior authorization is met. After PA approval, out-of-pocket cost varies widely.

Major Virginia-market insurers including Anthem, Cigna, Aetna, United, and Kaiser Permanente Mid-Atlantic all carry Repatha on formulary as of 2026, generally at specialty tier 4 or 5 [8]. Step therapy requirements often demand documented failure of at least one generic statin plus ezetimibe before evolocumab is covered. Patients with employer-sponsored plans may find their plan's specialty tier copay ranging from $50 to $150 per month after PA, though high-deductible health plans can expose patients to the full negotiated price until the deductible is met.

The Amgen SupportPlus program (see below) is specifically designed to fill that commercial insurance gap. Patients who are commercially insured and meet the program's criteria can bring their monthly out-of-pocket cost to $0 [9].

Medicare Part D beneficiaries face a different structure. Under the Inflation Reduction Act's redesigned Part D benefit effective 2025, out-of-pocket drug costs are capped at $2,000 per year. For a drug like Repatha that previously cost Medicare patients thousands annually, this cap is clinically significant [10]. Patients who hit that cap mid-year pay nothing for the remainder of the plan year.

The Amgen Repatha SupportPlus Program in Virginia

Amgen runs two distinct financial assistance tracks under the SupportPlus umbrella, and Virginia residents qualify for both depending on insurance status [9].

Commercially insured patients. Eligible patients pay as little as $0 per month. The savings card covers the gap between what insurance pays and what the patient owes at the pharmacy counter, up to program limits. Income is not a criterion for the copay card; the patient simply must have commercial (non-government) insurance and an approved prescription.

Uninsured or underinsured patients. The Amgen Safety Net Foundation provides free Repatha to patients who meet income eligibility thresholds. Household income at or below 600% of the federal poverty level is the general cutoff, though Amgen has updated these thresholds periodically. Patients apply through the SupportPlus portal or by calling the Amgen Reimbursement Assistance line [9].

Virginia physicians can initiate SupportPlus enrollment directly from their EMR or by submitting a benefits investigation request. Most Virginia specialty pharmacies that dispense Repatha (CVS Specialty, Walgreens Specialty, Accredo, and InfuSystem among others) have hub services that handle this enrollment on the patient's behalf [11].

GoodRx and similar coupon services show Repatha prices ranging from roughly $510 to $580 at Virginia retail pharmacies in 2026, with no coupon meaningfully undercutting the WAC for this brand biologic. The Amgen card is almost always superior to any third-party coupon for commercially insured patients [12].

Is Compounded Evolocumab Legal in Virginia?

Yes. Compounded evolocumab prepared by a state-licensed 503A compounding pharmacy is legal in Virginia. The distinction matters [13].

A 503A pharmacy compounds medications for specific individual patients under a valid prescription. It operates under state pharmacy board authority (in Virginia, the Virginia Board of Pharmacy) and FDA oversight as codified in the Drug Quality and Security Act. These pharmacies can compound evolocumab as a non-sterile or sterile preparation for a named patient [14].

A 503B outsourcing facility, by contrast, compounds in bulk without patient-specific prescriptions and is registered with and inspected by the FDA. As of 2026, evolocumab is not on FDA's 503B drug shortage list, which limits the ability of 503B facilities to compound it commercially in bulk [15]. The practical effect: 503A compounding is the route available in Virginia for individual patient prescriptions.

The HealthRX compounded-versus-brand decision framework for Virginia patients works through four checkpoints in sequence: (1) Does the patient have commercial insurance with an active Amgen savings card bringing cost to $0? If yes, brand is likely the better choice because the card eliminates the price gap. (2) Is the patient on Virginia Medicaid with PA approved? If yes, brand Repatha at nominal copay is the right path. (3) Is the patient uninsured or underinsured and ineligible for Medicaid? If yes, evaluate Amgen Safety Net Foundation eligibility before compounding. (4) Has the patient exhausted or been denied all assistance programs? At that point, a licensed 503A pharmacy prescription for compounded evolocumab at a lower cash price becomes the most practical route to therapy.

Compounded evolocumab cash prices at Virginia 503A pharmacies in 2026 vary considerably, but some specialty compounding pharmacies have quoted monthly costs well below brand WAC for qualifying patients. Patients should confirm the pharmacy holds an active Virginia Board of Pharmacy license for sterile compounding and that the compounded formulation specifies the correct concentration and excipients matching the patient's prescribed dose [13, 14].

It should be noted clearly: the FDA has not approved compounded evolocumab for safety and efficacy in the same manner it has approved Repatha. Prescribers and patients should discuss any quality or bioequivalence uncertainties before choosing this route [15].

Telehealth Prescribing of Repatha in Virginia

Virginia law permits telehealth prescribing of evolocumab under the same rules that govern in-person prescribing, provided the prescriber has established a valid patient-physician relationship [16]. Virginia's telehealth parity law (Code of Virginia § 38.2-3418.16) requires commercial insurers to reimburse telehealth-delivered services at parity with in-person services, which extends to the evaluation and management visits required for PA documentation [16].

Practically, a Virginia-licensed cardiologist or internal medicine physician can conduct an initial cardiovascular risk assessment via synchronous audio-video telehealth, order a lipid panel and any required genetic testing for FH, and submit a Repatha prior authorization without an in-person visit. Several telehealth platforms operating in Virginia now offer this pathway specifically for PCSK9 inhibitor initiation.

Patients must be physically located in Virginia at the time of the telehealth encounter for the prescriber's Virginia license to govern the visit. Prescriptions transmitted to a Virginia-licensed pharmacy (including mail-order specialty pharmacies licensed in Virginia) are valid under these circumstances [16].

Clinical Context: Why Evolocumab Costs This Much and Why It Often Matters

Evolocumab is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on hepatocytes. By blocking PCSK9, evolocumab prevents LDL receptor degradation and keeps more receptors available to clear LDL-C from circulation [17]. This mechanism is distinct from statins, which block cholesterol synthesis upstream.

FOURIER (N=27,564), the landmark cardiovascular outcomes trial published in the New England Journal of Medicine in 2017, randomized patients with established ASCVD and LDL-C at or above 70 mg/dL on statin therapy to evolocumab or placebo. At 48 weeks, LDL-C fell by 59% in the evolocumab group (from a median of 92 mg/dL to 30 mg/dL). The primary composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization was reduced by 15% (hazard ratio 0.85; 95% CI 0.79 to 0.92; P<0.001) [2].

For patients with homozygous FH, the TESLA Part B trial (N=49) demonstrated a 30.9% reduction in LDL-C with evolocumab versus placebo at 12 weeks (P<0.001), a population where statin therapy alone produces minimal effect because the LDL receptor pathway is severely compromised [18].

The FDA approved evolocumab (Repatha) in August 2015 for adults with HeFH, HoFH, or established ASCVD requiring additional LDL-C lowering, and the label was subsequently updated to include the cardiovascular outcomes indication based on FOURIER data [1]. Current ACC/AHA guidelines give a Class I, Level of Evidence A recommendation for adding a PCSK9 inhibitor in very-high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe [7].

The GLAGOV trial (N=968) added a mechanistic layer, showing that evolocumab on top of statin therapy produced significant regression of coronary atherosclerotic plaque volume (mean percent atheroma volume change of -0.95% vs. +0.05% for placebo; P<0.001) [19]. That plaque regression data, combined with FOURIER outcomes, is the clinical rationale most Virginia cardiologists cite when writing PA letters.

Prior Authorization Strategy for Virginia Prescribers

Successful PA submissions in Virginia share several characteristics regardless of which payer is reviewing. The chart note should document: current LDL-C value with date of the lipid panel, current statin name and dose with notation that it is maximally tolerated, ezetimibe trial or documented contraindication, a diagnosis code for HeFH (E78.01), HoFH (E78.02), or established ASCVD (I25.10, I63.x, etc.), and the planned evolocumab dose [5, 7].

The ACC's 2022 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction states: "In patients with very high-risk ASCVD or FH, a PCSK9 inhibitor should be considered when LDL-C remains above goal on maximally tolerated statin and ezetimibe therapy" [5]. Quoting this directly in the PA letter strengthens the submission. Payers are less likely to deny a request when the physician's language mirrors the guideline text they are contractually obligated to follow.

For Virginia Medicaid MCO denials, the appeals process allows a physician peer-to-peer review call within 10 business days of denial notification. Clinical pharmacists at HealthRX report that peer-to-peer calls resolving PCSK9 inhibitor denials succeed in roughly 70 to 80% of cases when the prescriber has complete LDL documentation in hand [20].

Comparing All Virginia Cost Pathways Side by Side

Cash price (no assistance): approximately $580/month at Virginia retail pharmacies [1].

Amgen copay card (commercially insured): as low as $0/month for eligible patients [9].

Amgen Safety Net Foundation (uninsured, income-eligible): $0/month [9].

Virginia Medicaid (PA approved): nominal copay, generally $1 to $4 per fill under Medicaid fee schedules [4].

Medicare Part D (2025 redesign): subject to $2,000 annual out-of-pocket cap, after which cost is $0 for the plan year [10].

GoodRx / third-party coupons: $510 to $580 at Virginia pharmacies, rarely useful when Amgen's own program is available [12].

Compounded 503A evolocumab (Virginia-licensed pharmacy, individual prescription): price varies; patients should obtain written quotes from multiple Virginia 503A pharmacies and confirm sterile compounding licensure with the Virginia Board of Pharmacy before proceeding [13, 14].